Madoka Takeuchi

1.7k total citations · 1 hit paper
19 papers, 1.3k citations indexed

About

Madoka Takeuchi is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Madoka Takeuchi has authored 19 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cardiology and Cardiovascular Medicine, 5 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Madoka Takeuchi's work include Cardiovascular Function and Risk Factors (6 papers), Heart Failure Treatment and Management (6 papers) and Blood Pressure and Hypertension Studies (3 papers). Madoka Takeuchi is often cited by papers focused on Cardiovascular Function and Risk Factors (6 papers), Heart Failure Treatment and Management (6 papers) and Blood Pressure and Hypertension Studies (3 papers). Madoka Takeuchi collaborates with scholars based in United States, Japan and Indonesia. Madoka Takeuchi's co-authors include Scott D. Solomon, John J.V. McMurray, Amil M. Shah, Marty Lefkowitz, Toni Bransford, Burkert Pieske, Michael R. Zile, Elisabeth Kraigher‐Krainer, Jianjian Gong and Milton Packer and has published in prestigious journals such as The Lancet, Circulation and Journal of Clinical Oncology.

In The Last Decade

Madoka Takeuchi

19 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

2012 883 citations Scott D. Solomon, Michael R. Zile et al. The Lancet profile →

Peers

Countries citing papers authored by Madoka Takeuchi

Since Specialization

Citations

This map shows the geographic impact of Madoka Takeuchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Madoka Takeuchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Madoka Takeuchi more than expected).

Fields of papers citing papers by Madoka Takeuchi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Madoka Takeuchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Madoka Takeuchi. The network helps show where Madoka Takeuchi may publish in the future.

Co-authorship network of co-authors of Madoka Takeuchi

This figure shows the co-authorship network connecting the top 25 collaborators of Madoka Takeuchi. A scholar is included among the top collaborators of Madoka Takeuchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Madoka Takeuchi. Madoka Takeuchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Correlation of multiple endpoints in the first‐line chemotherapy of advanced gastric cancer: Pooled analysis of individual patient data from Japanese Phase III trials 2023 ·Cancer Medicine ·Hiroyuki Arai, Madoka Takeuchi, Wataru Ichikawa, Kohei Shitara, Yu Sunakawa, Koji Oba, Wasaburo Koizumi, Yuh Sakata, Hiroshi Furukawa, Yasuhide Yamada, Masahiro Takeuchi, Masashi Fujii	3
2	Effect of Late Androgen Replacement Therapy on Erectile Function Through Structural Changes in Castrated Rats 2021 ·Sexual Medicine ·Tomoya Kataoka, Yuji Hotta, Yuka Yamamoto, (unknown), Madoka Takeuchi, Yasuhiro Maeda, Kazunori Kimura	9
3	S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial 2017 ·The Lancet. Gastroenterology & hepatology ·Masatoshi Kudo, Michihisa Moriguchi, Kazushi Numata, Hisashi Hidaka, Hironori Tanaka, Masafumi Ikeda, Seiji Kawazoe, Shinichi Ohkawa, Yozo Sato, Shuichi Kaneko, Junji Furuse, Madoka Takeuchi, (unknown), (unknown), Masahiro Takeuchi, Takuji Okusaka	42
4	Identification of patient population with longer survival when treated with S-1 plus cisplatin via predictive enrichment strategy analysis of the FLAGS phase III trial. 2017 ·Journal of Clinical Oncology ·Jaffer A. Ajani, Madoka Takeuchi, Masahiro Takeuchi	1
5	Identification of a high-response patient population to S-1 via predictive enrichment strategy analysis of the S-CUBE phase III trial. 2016 ·Journal of Clinical Oncology ·Masatoshi Kudo, Takuji Okusaka, Shuichi Kaneko, Junji Furuse, Madoka Takeuchi, (unknown), (unknown), Masahiro Takeuchi	3
6	Traditional Risk Factors Versus Biomarkers for Prediction of Secondary Events in Patients With Stable Coronary Heart Disease: From the Heart and Soul Study 2015 ·Journal of the American Heart Association ·Alexis L. Beatty, Ivy Ku, Kirsten Bibbins‐Domingo, Robert H. Christenson, Christopher R. deFilippi, Peter Ganz, Joachim H. Ix, Donald M. Lloyd‐Jones, Torbjørn Omland, Marc S. Sabatine, Nelson B. Schiller, Michael G. Shlipak, Hicham Skali, Madoka Takeuchi, Eric Vittinghoff, Mary A. Whooley	47
7	Heart Failure With Preserved Ejection Fraction in African Americans 2013 ·JACC Heart Failure ·Deepak K. Gupta, Amil M. Shah, Davide Castagno, Madoka Takeuchi, Laura R. Loehr, Ervin R. Fox, Kenneth R. Butler, Thomas H. Mosley, Dalane W. Kitzman, Scott D. Solomon	54
8	Right Ventricular Function, Pulmonary Pressure Estimation, and Clinical Outcomes in Cardiac Resynchronization Therapy 2013 ·Circulation Heart Failure ·Patricia Campbell, Madoka Takeuchi, Mikhail Bourgoun, Amil M. Shah, Elyse Foster, Mary W. Brown, Ilan Goldenberg, David T. Huang, Scott McNitt, William J. Hall, Arthur J. Moss, Marc A. Pfeffer, Scott D. Solomon	35
9	Differential Influence of Distinct Components of Increased Blood Pressure on Cardiovascular Outcomes 2013 ·Hypertension ·Susan Cheng, Deepak K. Gupta, Brian Claggett, A. Richey Sharrett, Amil M. Shah, Hicham Skali, Madoka Takeuchi, Hanyu Ni, Scott D. Solomon	10
10	Utility of Lung Ultrasound in Predicting Pulmonary and Cardiac Pressures 2012 ·European Journal of Heart Failure ·Elke Platz, (unknown), (unknown), Madoka Takeuchi, Frederic S. Resnic, Scott D. Solomon, Akshay S. Desai	43
11	Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart Failure 2012 ·Journal of the American College of Cardiology ·Davide Castagno, Hicham Skali, Madoka Takeuchi, Karl Swedberg, Salim Yusuf, Christopher B. Granger, Eric L. Michelson, Marc A. Pfeffer, John J.V. McMurray, Scott D. Solomon	129
12	The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial breakdown → 2012 ·The Lancet ·Scott D. Solomon, Michael R. Zile, Burkert Pieske, Adriaan A. Voors, Amil M. Shah, Elisabeth Kraigher‐Krainer, Victor Shi, Toni Bransford, Madoka Takeuchi, Jianjian Gong, Marty Lefkowitz, Milton Packer, John J.V. McMurray	883
13	The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial 2012 ·Journal of Cardiac Failure ·Scott D. Solomon, Michael R. Zile, Burkert Pieske, Adriaan A. Voors, Amil M. Shah, Elisabeth Kraigher‐Krainer, Victor Shi, Toni Bransford, Madoka Takeuchi, Jianjian Gong, Martin Lefkowitz, Milton Packer, John J.V. McMurray	5
14	Current status of phase I clinical trials in Asia: an academic perspectives. 2012 ·PubMed ·Melva Louisa, Masahiro Takeuchi, Rianto Setiabudy, (unknown), Madoka Takeuchi	9
15	Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression 2012 ·Journal of the Renin-Angiotensin-Aldosterone System ·Orly Vardeny, Anne–Catherine Pouleur, Madoka Takeuchi, Evan Appelbaum, Anil Verma, Margaret F. Prescott, Beverly A. Smith, Björn Dahlöf, Scott D. Solomon, (unknown)	4
16	Left Ventricular Systolic and Diastolic Function, Remodelling, and Clinical Outcomes Among Patients with Diabetes Following Myocardial Infarction and the Influence of Direct Renin Inhibition with Aliskiren 2011 ·European Journal of Heart Failure ·Amil M. Shah, Sung‐Hee Shin, Madoka Takeuchi, Hicham Skali, Akshay S. Desai, Lars Køber, Aldo P. Maggioni, Jean L. Rouleau, Roxzana Y. Kelly, Allen Hester, Deborah Keefe, John J.V. McMurray, Marc A. Pfeffer, Scott D. Solomon	38
17	Abstract 17352: Incidence and Predictors of Stroke in Patients with Chronic Heart Failure: Does Left Ventricular Function Matter? Insights From the CHARM Program 2011 ·Circulation ·Davide Castagno, Hicham Skali, Madoka Takeuchi, Karl Swedberg, Salim Yusuf, Christopher B. Granger, Marc A. Pfeffer, John J.V. McMurray, Scott D. Solomon	1
18	A meta-analysis on treatment effects of thiazolidinediones for type 2 diabetes mellitus in Asian populations. 2011 ·PubMed ·Melva Louisa, Madoka Takeuchi, Masahiro Takeuchi, (unknown), Rianto Setiabudy	3
19	Incretin-based therapies for type 2 diabetes mellitus in Asian patients: Analysis of clinical trials 2010 ·Medical Journal of Indonesia ·Melva Louisa, Madoka Takeuchi, Masahiro Takeuchi, (unknown), Rianto Setiabudy	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact